News stories about Aralez Pharmaceuticals (NASDAQ:ARLZ) have been trending somewhat positive on Sunday, according to Accern Sentiment Analysis. The research group identifies positive and negative media coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Aralez Pharmaceuticals earned a daily sentiment score of 0.14 on Accern’s scale. Accern also gave news stories about the company an impact score of 45.3820365924835 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
Separately, Chardan Capital cut their target price on Aralez Pharmaceuticals from $5.50 to $4.00 and set a “buy” rating for the company in a research note on Thursday, August 10th.
Shares of Aralez Pharmaceuticals (ARLZ) traded down 2.01% during mid-day trading on Friday, hitting $1.46. The company’s stock had a trading volume of 599,087 shares. Aralez Pharmaceuticals has a 12-month low of $0.95 and a 12-month high of $5.49. The stock has a 50-day moving average of $1.74 and a 200-day moving average of $1.45. The company’s market cap is $97.60 million.
Aralez Pharmaceuticals (NASDAQ:ARLZ) last posted its quarterly earnings data on Wednesday, August 9th. The company reported ($0.42) EPS for the quarter, missing analysts’ consensus estimates of ($0.41) by ($0.01). Aralez Pharmaceuticals had a negative return on equity of 90.17% and a negative net margin of 122.35%. The business had revenue of $27.62 million during the quarter, compared to the consensus estimate of $21.37 million. During the same quarter in the previous year, the firm posted ($0.27) earnings per share. The company’s revenue for the quarter was up 119.6% on a year-over-year basis. On average, equities research analysts forecast that Aralez Pharmaceuticals will post ($1.62) EPS for the current year.
ILLEGAL ACTIVITY NOTICE: This report was first posted by TrueBlueTribune and is the property of of TrueBlueTribune. If you are reading this report on another domain, it was stolen and republished in violation of international copyright law. The original version of this report can be read at https://www.truebluetribune.com/2017/10/22/aralez-pharmaceuticals-arlz-receives-news-sentiment-rating-of-0-14.html.
About Aralez Pharmaceuticals
Aralez Pharmaceuticals Inc is a Canada-based specialty pharmaceutical company. The Company focuses on acquiring, developing and commercializing products in cardiovascular, pain and other areas. The Company’s products include Fibricor, Cambia, Fiorinal, Fiorinal C, Soriatane, Bezalip SR, NeoVisc, Uracyst, Durela, Proferrin, Resultz and Collatamp G.
Receive News & Ratings for Aralez Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aralez Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.